BI's Mirapex ER approved in US for advanced Parkinson's disease
This article was originally published in Scrip
Executive Summary
The US FDA has approved Boehringer Ingelheim's Mirapex ER (pramipexole hydrochloride) as a once daily treatment for the signs and symptoms of advanced idiopathic Parkinson's disease (PD). The prolonged-release drug was approved earlier this year for early PD in the US, and is approved in the EU for both early and advanced PD.